Thus, this double-armed oncolytic virus is capable of activating neoantigen-specific T cell responses by the likely synergistic action of PD-L1 inhibition on tumor cells and immune cells, viral replication, and GM-CSF stimulation. The gene discussed is CSF2; the disease is neoplasm.